Boston Scientific’s $3.7B Axonics buy tops list of medtech M&A in 2024
Wall Street analysts tipped 2024 as the year that medtech dealmaking would return after a two-year slowdown when companies were forced to navigate a tough economic environment, complicated by the COVID-19 pandemic still pressuring businesses. There have …